Abstract:Background: Energy metabolism deficiency is part of the acute kidney injury (AKI) pathophysiology. Recent studies highlighted the role of nicotinamide adenine dinucleotide (NAD) production in the pathogenesis of AKI. NAD is an electron carrier for mitochondria and a cofactor for cytoplasmic redox reactions. Its production is decreased during AKI following a decrease of the expression of PGC1 α (Peroxisome proliferator activated receptor gamma co-activator-1-α ) and an alteration of its de novo synthesis pathway: with a reduction in the expression of the Quinolinate PhosphoRibosylTransferase (QPRT). The modulation of this de novo pathway has been studied mainly in the acute phase immediately after AKI. However, its correlation with the severity of the ischemic insult and its evolution during the transition from AKI to CKD have not been described yet. Methods: Renal ischemia-reperfusion was performed in C57Bl6/J male mice after nephrectomy of the contralateral kidney. For the ’severity’ study, a 5-30 minutes ischemia was performed. Renal function was assessed 24h after ischemia. For the ‘AKI to CKD’ study, renal ischemia was performed during 10 minutes. Mice were sacrificed 1, 2, 3, 6 and 28 days after ischemia. PGC1 α and QPRT mRNA expression was measured by RT-qPCR. Results: We induced AKI in mice by unilateral ischemia reperfusion injury of increasing time to induce several degrees of AKI severity. PGC1 α and QPRT mRNA expression decreased progressively with ischemia severity until reaching a plateau at 15 minutes of ischemia for PGC1 α , like plasma creatinine and urea, whereas QPRT decrease is linear until 30 min of ischemia. PGC1 α mRNA decrease is also inversely correlated to kidney dysfunction (p<0.001). A 10-minute ischemia led to the development of Chronic Kidney Disease (CKD), as evidenced by an incomplete recovery of the kidney function at 28 days. QPRT and PGC1 α mRNA expression showed a progressive but incomplete recovery during the transition from AKI to CKD compared to sham mice. Conclusions: In addition to confirming the decrease of PGC α and QPRT mRNA expression during AKI, we show that it is correlated to the severity of the ischemic AKI. Furthermore, we describe the recovery during renal repair and transition to CKD.

Nicotinamide riboside: A promising therapy for MI-induced acute kidney injury by upregulating nicotinamide phosphoribosyltransferase-mediated NAD levels

Effect of NAD+ boosting on kidney ischemia-reperfusion injury

Nicotinamide Riboside-Driven Modulation of SIRT3/mtROS/JNK Signaling Pathways Alleviates Myocardial Ischemia-Reperfusion Injury

Nicotinamide ribose ameliorates myocardial ischemia/reperfusion injury by regulating autophagy and regulating oxidative stress

Nicotinamide Retains Klotho Expression and Ameliorates Rhabdomyolysis-Induced Acute Kidney Injury.

Nicotinamide Mononucleotide Attenuates Renal Interstitial Fibrosis after AKI by Suppressing Tubular DNA Damage and Senescence

Nicotinamide riboside attenuates myocardial ischemia-reperfusion injury via regulating SIRT3/SOD2 signaling pathway

Nicotinamide riboside activates renal metabolism and protects the kidney in a model of Alport syndrome

Protective Effect of Nicotinamide Adenine Dinucleotide Phosphate on Renal Ischemia-Reperfusion Injury

Nicotinamide Riboside Alleviates Cardiac Dysfunction and Remodeling in Pressure Overload Cardiac Hypertrophy

Nicotinamide Attenuates the Progression of Renal Failure in a Mouse Model of Adenine-Induced Chronic Kidney Disease

NAD+ precursor supplementation prevents mtRNA/RIG-I-dependent inflammation during kidney injury

Nicotinamide Mononucleotide Protects against Retinal Dysfunction in a Murine Model of Carotid Artery Occlusion

Nicotinamide Riboside Attenuates Injury of Mouse Diabetic Cardiomyopathy and Possible Mechanism

Acute Treatment with Nicotinamide Riboside Chloride Reduces Hippocampal Damage and Preserves the Cognitive Function of Mice with Ischemic Injury

Ultrasmall Polyphenol‐NAD+ Nanoparticle‐Mediated Renal Delivery for Mitochondrial Repair and Anti‐Inflammatory Treatment of AKI‐to‐CKD Progression

Short-term Administration of Nicotinamide Mononucleotide Preserves Cardiac Mitochondrial Homeostasis and Prevents Heart Failure.

Kinetics of the De Novo NAD/NADH Pathway from AKI to CKD

Pre-emptive Short-term Nicotinamide Mononucleotide Treatment in a Mouse Model of Diabetic Nephropathy

NAD activates renal metabolism and protects from chronic kidney disease in a model of Alport syndrome

NAD+ enhancers as therapeutic agents in the cardiorenal axis